Fundamental Pharmacokinetic Properties
Ketamine is a phencyclidine derivative with a molecular weight of 237.7 daltons. It is moderately lipophilic, which facilitates rapid crossing of the blood-brain barrier and contributes to its swift onset of action when administered intravenously. The drug exists as a racemic mixture of two enantiomers, S(+)-ketamine (esketamine) and R(-)-ketamine (arketamine), each with distinct pharmacokinetic and pharmacodynamic profiles. S-ketamine demonstrates approximately three- to four-fold greater affinity for the NMDA receptor compared to R-ketamine and is cleared slightly faster from plasma. For a comparison of the enantiomers in clinical practice, see esketamine vs racemic dosing.
Understanding ketamine pharmacokinetics is foundational for rational dose selection, route choice, and timing of clinical assessments. The following sections address each pharmacokinetic parameter organized by the classic ADME framework.
Absorption and Bioavailability by Route
The route of administration profoundly influences ketamine pharmacokinetics, particularly bioavailability and time to peak plasma concentration (Tmax).
Intravenous Administration
Intravenous (IV) delivery provides 100 percent bioavailability by definition and is the reference standard for pharmacokinetic comparisons. When administered as a 0.5 mg/kg infusion over 40 minutes, peak plasma concentrations typically reach 150 to 250 ng/mL. Onset of central nervous system effects occurs within minutes of infusion initiation.
Intramuscular Administration
Intramuscular (IM) injection yields a bioavailability of approximately 93 percent. Absorption is rapid, with Tmax occurring at 15 to 30 minutes. This route is commonly used in emergency and field settings where IV access is unavailable. Peak plasma concentrations are somewhat lower and more variable than IV delivery due to differences in muscle blood flow and injection site.
Intranasal Administration
Intranasal bioavailability ranges from 25 to 50 percent, with considerable interpatient variability attributed to mucosal vascularity, nasal congestion, administration technique, and formulation characteristics. Tmax is typically 20 to 40 minutes. The FDA-approved esketamine nasal spray (Spravato) uses a standardized delivery device to improve consistency. First-pass metabolism is partially bypassed via nasal absorption directly into the systemic circulation through the richly vascularized nasal mucosa.
Sublingual and Oral Administration
Sublingual ketamine achieves bioavailability of approximately 25 to 30 percent, while oral bioavailability is notably lower at 16 to 24 percent due to extensive first-pass hepatic metabolism. Oral administration results in higher plasma ratios of norketamine relative to ketamine, which may have clinical implications given the emerging evidence for norketamine's own pharmacological activity. Tmax for oral ketamine is typically 30 to 60 minutes.
Subcutaneous Administration
Subcutaneous injection, increasingly studied in palliative care and chronic pain contexts, yields bioavailability comparable to the intramuscular route, estimated at approximately 90 percent. Absorption is slightly slower than IM, with Tmax at 20 to 45 minutes.
Distribution
Ketamine distributes rapidly into highly perfused tissues, including the brain, following a two- or three-compartment pharmacokinetic model. The volume of distribution at steady state is approximately 3 to 5 L/kg, reflecting extensive tissue uptake. Plasma protein binding is relatively low at approximately 12 to 47 percent, primarily to alpha-1-acid glycoprotein and albumin. The rapid redistribution from brain tissue to peripheral compartments accounts for the relatively brief duration of clinical effect following a single bolus dose, despite a longer terminal elimination half-life.
Metabolism
Hepatic biotransformation is the primary route of ketamine clearance. The principal metabolic pathway involves N-demethylation to norketamine (also known as metabolite II), catalyzed predominantly by cytochrome P450 enzymes CYP3A4 and CYP2B6. Norketamine retains approximately one-third of the anesthetic potency of the parent compound and may contribute meaningfully to both therapeutic and adverse effects, particularly following oral administration where norketamine-to-ketamine ratios are elevated.
Norketamine undergoes further hydroxylation to hydroxynorketamine (HNK) isomers and subsequent glucuronide conjugation for renal excretion. The metabolite (2R,6R)-hydroxynorketamine has attracted significant research interest after preclinical studies suggested it possesses antidepressant activity independent of NMDA receptor blockade, potentially acting through AMPA receptor potentiation. However, clinical confirmation of this hypothesis remains ongoing.
Hepatic clearance of ketamine is high, approximately 12 to 20 mL/kg/min, making it a flow-dependent drug. Conditions that reduce hepatic blood flow, such as congestive heart failure, cirrhosis, or concurrent use of drugs that diminish hepatic perfusion, can significantly prolong ketamine elimination.
Elimination Half-Life
The terminal elimination half-life of racemic ketamine is approximately 2 to 3 hours in healthy adults, though this figure represents the slowest phase of a multicompartmental decline. The distribution half-life (alpha phase) is much shorter, on the order of 10 to 15 minutes, which is more clinically relevant for the duration of acute psychoactive effects after a single bolus.
S-ketamine has a slightly shorter half-life than R-ketamine, consistent with its more rapid hepatic clearance. Norketamine has an elimination half-life of approximately 5 to 8 hours, and hydroxynorketamine metabolites may persist even longer, with half-lives exceeding 12 hours in some studies.
Clinical Pharmacokinetic Considerations
Clinicians prescribing low-dose ketamine should recognize that pharmacokinetic variability between patients can be substantial. Age, hepatic function, body composition, genetic polymorphisms in CYP2B6 and CYP3A4, and concurrent medications all influence drug exposure. Obese patients may require dose adjustments based on ideal or adjusted body weight rather than total body weight, as ketamine's lipophilicity leads to increased distribution into adipose tissue without proportional increases in clearance. Monitoring for prolonged effects in patients with hepatic impairment is advisable, and drug interaction screening should include attention to CYP3A4 inhibitors and inducers that may alter ketamine metabolism.
References
- PubMed: Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics — Definitive review of ketamine ADME parameters across routes of administration
- PubMed: Ketamine Pharmacokinetics — Pharmacokinetic modeling of ketamine and metabolite disposition
- PubChem: Ketamine Compound Summary — NCBI PubChem entry for ketamine physicochemical properties, molecular weight, and lipophilicity
- DailyMed: FDA Drug Label Information — National Library of Medicine database of official FDA drug labeling including pharmacokinetic data
Share